CClinicalTrials.gg
Not yet recruitingNCT07434076Updated Feb 25, 2026

Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine

An observational study in Psoriasis and Atopic Dermatitis, sponsored by Shanghai Yueyang Integrated Medicine Hospital. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Shanghai Yueyang Integrated Medicine Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
950
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a cross-sectional, observational investigation designed to develop and validate a noninvasive ocular imaging-based predictive model for major inflammatory skin diseases, including psoriasis, atopic dermatitis, and urticaria. Grounded in Traditional Chinese Medicine (TCM) ocular diagnostic theory and integrated with advanced computer vision techniques, the study aims to establish objective, quantifiable biomarkers derived from scleral and bulbar conjunctival images.

Approximately 950 participants (patients with psoriasis, atopic dermatitis, urticaria, and healthy controls) will be recruited from a tertiary academic hospital. Standardized high-resolution ocular images will be collected alongside comprehensive clinical, demographic, and comorbidity data. Disease severity will be assessed using validated clinical scoring systems (e.g., PASI, EASI, UAS7, DLQI).

Image analysis will combine traditional radiomics feature extraction with deep learning architectures, including a Vision State-Space (VMamba) module for global-local feature representation and a Multi-Gate Mixture-of-Experts (MMoE) framework for multi-task learning. The model is designed to simultaneously perform disease classification and predict comorbidity risks (such as metabolic syndrome, hepatic insulin resistance, and recurrence risk).

Primary outcomes include characterization of ocular feature patterns associated with inflammatory skin diseases. Secondary outcomes include correlations between ocular image-derived features and clinical severity indices. Model performance will be evaluated using ROC curves, AUC, calibration analysis, and decision curve analysis.

This study aims to provide an objective, digitalized, and clinically applicable ocular biomarker framework to support early diagnosis, risk stratification, and comorbidity screening in inflammatory skin diseases.

02

Conditions studied

  • Psoriasis
  • Atopic Dermatitis
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

As an exploratory cross-sectional study involving high-dimensional image-omics modeling, we plan to enlarge the sample size. We intend to recruit 200 cases each of psoriasis, atopic dermatitis, and urticaria, and 150 healthy controls. The dataset will be split into training and internal validation sets at an 8:2 ratio. An external independent validation cohort of 200 subjects is planned. The total sample size is therefore approximately 950 participants.

Inclusion criteria

For patients with inflammatory skin disease:

Clinical diagnosis of one of the three target inflammatory skin diseases (psoriasis, atopic dermatitis, or urticaria).

Age ≥ 18 and ≤ 65 years, any sex.

Understands and signs informed consent.

For healthy controls:

Do not meet diagnostic criteria for any of the three inflammatory skin diseases above.

Age ≥ 18 and ≤ 65 years, any sex.

Understands and signs informed consent.

Exclusion criteria

Exclusion Criteria:

For patients with inflammatory skin disease:

Exclude any subject meeting any of the following:

Refusal to undergo examinations.

Presence of acute/active infectious ocular disease (e.g., viral keratoconjunctivitis).

Corneal perforation or high-risk perforation where contact procedures cause severe photophobia, eye pain, inability to keep eyes open or fixate.

Nystagmus or other conditions that prevent fixation.

Pupillary non-dilation (e.g., posterior synechiae) that precludes fundus imaging.

Severe eyelid lesions (e.g., marked swelling, ectropion, entropion) that prevent globe exposure.

Participation in other clinical trials within the previous 3 months or concurrent participation in other interventional studies.

  • Healthy control - exclusion criteria

Exclude any subject meeting any of the following:

Presence of other skin diseases that could affect study assessments (e.g., atopic dermatitis, urticaria, scabies).

Refusal to undergo examinations.

Acute/active infectious ocular disease (e.g., viral keratoconjunctivitis).

Corneal perforation or high-risk perforation that causes severe photophobia, eye pain, inability to keep eyes open or fixate during contact procedures.

Nystagmus or other reasons preventing fixation.

Pupillary non-dilation (e.g., posterior synechiae) that prevents fundus imaging.

Participation in other clinical studies within the previous 3 months or currently participating in other clinical trials.

04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
950 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Psoriasis subjects

    Other: Questionnaire collection

  • Atopic dermatitis subjects

    Other: Questionnaire collection

  • Urticaria subjects

    Other: Questionnaire collection

  • Healthy controls

    Other: Questionnaire collection

Interventions

  • OtherQuestionnaire collection

    During the study visit investigators will conduct face-to-face interviews and collect the questionnaire data, with confirmation from family members where appropriate.

05

What researchers measure

Primary outcomes

  1. A TCM ocular diagnostic feature spectrum

    A TCM ocular diagnostic feature spectrum: overall prevalence and pattern combinations of ocular features in the psoriasis group. Incidence rates of characteristic ocular change

    Time frame: 2026.03.05-2028.03.05

Secondary outcomes

  1. Correlations (Spearman's rho) between ocular feature scores and clinical severity scales

    Correlations (Spearman's rho) between ocular feature scores and clinical severity scales: PASI, BSA, DLQI, VAS, EASI, UAS, and UCT

    Time frame: 2026.03.05-2028.03.05

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07434076
Lead sponsor
Shanghai Yueyang Integrated Medicine Hospital
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Mar 5, 2026 (estimated)
Primary completion
Mar 5, 2028 (estimated)
Completion
May 25, 2028 (estimated)
Last update
Feb 25, 2026

Study contacts

Xin Li, PhD
Contact
13661956326@163.com
13661956326

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion